glp
Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity
Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebr…
Ozempic and Zepbound users face 6 rebound risks after stopping, doctor warns
Thinking of quitting a GLP-1? A physician outlines six risks, from weight regain and muscle loss to worsening biomarkers and mental health consequences.
Millions in US use unapproved GLP-1s—and use them in unapproved ways
Cost and access barriers are pushing people to modified use and unapproved versions.
Halloween meets GLP-1s: Hershey’s candy Super Bowl, with CEO Kirk Tanner
The second a brand like Hershey stops being culturally relevant, says its CEO Kirk Tanner, you should be worried. He joins Rapid Response to explain exactly wha…
The GLP-1 Side Effect Everyone Ignores With Professor Clare Collins (493)
When Robbie Williams announced he had been diagnosed with s curvy earlier this year, Professor Clare Collins was relieved… why?! Because he was bringing attenti…
